Abstract. PR (PRdI-BFI and RIZ) domain containing (PRdM) proteins have been shown to be important in several types of human cancer. PRdM13, a member of the PRdM family, contains transcriptional regulators involved in modulating several cellular processes. However, the function of PRdM13 in glioma remains to be elucidated. The purpose of the present study was to evaluate the expression and effect of PRdM13 on glioma cells. It was found that the expression of PRdM13 was reduced in glioma cells, and the overexpression of PRdM13 significantly decreased the proliferation, migration and invasion of U87 glioma cells. Through validation of RNA-sequencing analysis, genes regulating cell proliferation and migration were classified from Gene Ontology sources. In addition, PRDM13 was shown to be associated with Rho protein and GTP enzyme activation protein. The over expression of PRdM13 upregulated deleted in liver cancer 1 (dLc1) to inhibit the proliferation and invasion of U87 cells. In conclusion, PRdM13 decreased the proliferation and invasion of U87 cells, and may be of potential value for glioma therapy.
Introduction
The PRdI-BFI and RIZ homology domain containing (PRdM) family contains 17 orthologs in primates, and 16 orthologs in rodents, birds and amphibians, the regulation of which has been associated with cancer.
PRDM2 was the first tumor suppressor identified within the PRdMs whose expression causes apoptosis and/or cell cycle arrest in cancer cell lines, and suppresses tumor growth in vivo (1, 2) . PRDM1 was identified as a tumor suppressor of diffuse large B-cell lymphoma in two mouse models of PRDM1 deficiency in the B cell compartment (3) . PRDM3 and PRDM16 have been identified as different isoforms associated with leukemia (4, 5) , and PRdM5 is a potential tumor suppressor involved in cell adhesion and extracellular matrix formation along with several genes in the Wnt pathway (6) (7) (8) . Therefore, several members of the PRdM family can suppress tumors.
Following Basic Local Alignment Search Tool searches of the National center for Biology Information database, the present study focused on one of the PRdMs, PRdM13, which is expressed in the nervous system. PRdM13 encodes a protein containing an N-terminal PR domain and four zinc finger repeats, which mediate sequence-specific DNA binding and protein-protein interactions. However, to the best of our knowledge, neither the expression nor the role of PRdM13 in glioma has been reported. Glioma is a common central nervous system tumor, which is frequently life threatening, despite optimized treatment including neurosurgery, radiotherapy and chemotherapy. Therefore, it is necessary to understand the molecular mechanisms underlying the proliferation and migration of gliomas. In the present study, it was identified that the expression of PRdM13 was low in U87 cells, therefore, it was hypothesized that the upregulation of PRDM13 may be important for glioma development. Subsequently, the effects of PRdM13 on cell proliferation, migration and invasion were investigated in the U87 human glioma cell line. The results demonstrated that PRdM13 may upregulate anti-oncogenes to inhibit glioma progression. These findings suggested that the overexpression of PRdM13 may be a useful molecular target for treating human glioma.
Materials and methods
Cell lines and cell culture. The U87 cell line was purchased from the cell Bank of the chinese Academy of Sciences (Shanghai, china; http://www.biovector.net/search?wd=U87 Lentivirus construction and transfection. The PRdM13 lentivirus construct was designed by Shanghai GeneChem Co., Ltd. (Shanghai, China) and a GFP lentivirus was used as the negative control (Nc). PRdM13 was inserted into the Ubi-MCS-3FLAG-SV40-EGFP-IRES-puromycin lentiviral vector. The U87 cells were plated in a six-well plate and the cells were transfected with PRdM13 lentivirus and Nc lentivirus (LV control) at a multiplicity of infection of 10 with polybrene (Sigma-Aldrich; Merck Millipore, darmstadt, Germany). Non-transfected cells were used as controls. The cells were cultured in a 5% cO 2 incubator at 37˚C for a further 7 days. The expression of GFP was observed by fluorescence microscopy.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Total RNA was extracted using the RNA spin Mini RNA isolation kit (Axygen Scientific, Inc., Union City, CA, USA). cDNA was synthesized with the Promega Reverse Transcriptase system (Promega corporation, Madison, WI, USA). The PCR amplification was performed using Taq Master mix (TransGen Biotech Co., Ltd., Beijing, China). Thirty-one primer pairs of different genes were designed and tested. The PCR cycling conditions were as follows: 94˚C for 30 sec, followed by 40 repeats of 94˚C for 5 sec and 60˚C for 30 sec. The relative expression levels of the genes of interest were normalized to the levels of GAPDH. The results were quantified as target gene/GAPDH using the 2 -∆∆cq method (9). The primers used are shown in Table I . All measurements were performed in triplicate.
Western blot analysis. The cells were washed twice with cold PBS, and then lysed in cold lysis buffer. The mix solution was centrifuged at 29,040 g for 50 min at 4˚C. Following collection of the supernatant, the protein concentration was determined with the BCA method (Nanjing KeyGen Biotech co., Ltd., Nanjing, china), according to the manufacturer's protocol. A total of 50 µg of protein was loaded and separated by 8-10% SDS-PAGE, according to molecular weight, and then transferred onto PVdF membranes. Subsequently, the membranes were incubated with antibodies at 4˚C overnight. The antibodies used were as follows: PRdM13 (1:1,000; cat. no. ab40542), Flag (1:1,000; cat. no. ab192404), and deleted in liver cancer 1 (dLc1; 1:1,000; cat. no. ab1220) from Abcam (Cambridge, MA, USA), Rho GTPase activating protein 30 (ARHGAP30; 1:500; cat. no. AP4996b; Abgent Biotech co., Ltd., Wuhan, china), A disintegrin and metalloproteinase with thrombospondin motifs 12 (AdAMTS12; 1:500; cat. no. 24934-1-AP; ProteinTech Group, Inc., Wuhan, China), inhibitor of cyclin-dependent kinase (cdK) interacting with cyclin A1 (INcA1; 1:500; cat. no. bsm-7899R; BIOSS, Beijing, China), and GAPDH (1:6,000; cat. no. 60004-1-Ig; ProteinTech Group, Inc.). The membranes were washed and incubated with the secondary antibodies (1:10,000) at room temperature for 90 min, comprising goat anti-rabbit IgG (cat. no. bsm-0295G) and goat anti-mouse IgG (cat. no. bsm-0296G) from BIOSS. All antibodies were diluted in 5% skim milk (Bd difco, cat. no. 2332100, SBJBio, Nanjing, china). Finally, the membranes were developed and quantified using Odyssey cLx Infrared Imaging system software, Image Studio Version 4.0 (LI-cOR Biosciences, Lincoln, NE, USA).
Cell proliferation assay. Following transfection with lentiviruses expressing PRdM13 or the scramble control using polybrene, the U87 cells were cultured for 24 h. The cells were collected and seeded in 96-well plates at a density of 2,000 cells/well. cell proliferation rates were determined once per day for 5 days using a Cell Counting Kit-8 kit (TransGen Biotech co., Ltd.). The samples were assayed in triplicate and Od values were detected at 450 nm.
Flow cytometric analysis of cell cycle. The U87 cells were transfected with lentiviruses expressing PRdM13 or the scramble control. Following incubation for 72 h, the cells were washed twice with PBS solution, trypsinized and fixed with pre-cooled 70% alcohol at 4˚C overnight. The cells were washed with PBS and stained with propidium iodide (cell Cycle Detection kit; KeyGen Biotech Co., Ltd.) at 4˚C for 30 min. Flow cytometry was performed using a FAcScalibur (Bd Biosciences, Franklin Lakes, NJ, USA).
Wound-healing assay. The U87 cells were seeded in 60-mm cell culture plates and incubated at 37˚C overnight in DMEM with 10% FBS. Upon reaching 90% confluence, the cells were cultured in serum-free medium for 24 h. A 200-µl sterile pipette tip was used to create a '+' wound. The cells were washed twice with PBS to remove cell debris and grown in FBS-free medium. Images of the wounds were captured under a microscope and repeated three times in duplicate.
Transwell invasion assay. cell invasion was measured using Bd Biocoat™ Matrigel™ Invasion chambers (Bd Biosciences). Transwell chambers were coated with Matrigel at a final concentration of 1 mg/ml. A total of 1x10 4 cells/ml were seeded into the upper chamber with 100 µl serum-free dMEM, and 500 µl dMEM with 10% FBS medium was added into the lower chamber. The cells were incubated in a humidified environment with 5% CO 2 at 37˚C for 24 h. The cells on the top surface of the membrane were removed with a cotton swab, and the migratory cells on the bottom surface of the membrane were fixed in 90% alcohol for 30 min at room temperature. The chambers were washed with PBS and stained with 5% crystal violet for 30 min. Migratory cells in the bottom surface of the membrane were counted by light microscopy. A total of six high-power microscopic fields (magnification, x200) were randomly selected and images captured, and the cells were counted.
Transcriptome sequencing. The total RNA of cells with lentiviruses expressing either PRdM13 or the scramble control was extracted using TRIzol reagent. The integrity of total RNA was examined using a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc.). Transcriptome sequencing was performed by Vazyme Biotech Co., Ltd. (Nanjing, China). Significant differentially expressed genes and the gene ontology (GO) function enrichment were obtained between two groups.
Validation of RNA-sequencing (RNA-Seq) analysis by RT-qPCR and western blot analyses.
According to the transcriptome sequencing results, genes of interest were selected relative to the proliferation and migration function with the following criteria: P<0.05 and absolute fold change >2. RT-qPcR and western blot analyses were performed to validate the RNA-Seq analysis. The primers used are listed in Table I , and the methods for RT-qPcR and western blot analyses were as described above.
Chromatin immunoprecipitation (ChIP) assay. The chIP assay was performed using the Pierce™ Agarose chIP kit (cat. no. 26156; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Immunoprecipitated dNA enrichment was normalized relative to the input. The enrichment of each target sequence was determined by RT-qPcR analysis. Flag antibody (1:1,000; cat. no. ab192404, Abcam) was used to perform chIP. The primers used were as follows: dLc1 ChIP, forward 1 5'-CTC TCC GGA GGT CCT TTA GC-3'; DLC1 ChIP, reverse 1 5'-CCA GCC GTC TGT CTC TAG TGT-3'; DLC1 ChIP, forward 2 5'-CTT TGA AAA CGC GAG GTC AC-3'; and DLC1 ChIP, reverse 2 5'-TGC AAC CCA ATG ACT CAC CT-3'. All samples were assessed in triplicate.
Statistical analysis. All data are expressed as the mean ± standard deviation. Statistical analyses were performed using SPSS 17.0 software (SPSS, Inc., chicago, IL, USA). comparisons between the Nc group and the PRdM13 group were made using Student's t-test. P<0.05 was considered to indicate a statistically significant difference.
Results

Efficient transfection of Lenti-PRDM13 into the U87 cell line.
The lower expression of PRdM13 in U87 human glioma cells suggested that PRdM13 may be involved in glioma development. To examine the role of PRdM13 in gliomas, the Lenti-PRdM13 and Lenti-con (Nc) lentiviruses were Table I . Primer sequences for reverse transcription-quantitative polymerase chain reaction analysis.
Gene
Sense (5'-3') Antisense (5'-3')   RORA  AACGGGCTGACGGAACTTCA  GGGAAGGCTGTATGTCCAGGT  EGR1  TTCCCTGAGCCACAAAGCCA  GGAACCTGGAAGCCACCCTT  WNT7B  GTGGACGCTCGGGAGATCAA  TCCTGCCGGCCTCATTGTTA  BHLHE41  GAGAACGACACGGACACCGA  GGAGGCTCCTGCTTGATGGT  ROS1  CTCCCAGCTGCACCCTCTG  TGAGAGCCAAACAGCACCGA  PLEKHG5  AGAGCTCTGCCTGGCTGTTC  AGCAGGGTGGTCCTGATTCG  SNAI2  GCACTGCGATGCCCAGTCTA  TGCCGCAGATCTTGCAAACA  SEMA5A  CCTTGCCTTGGCCCATCTCT  GAGCAAGAGCGGGTCCTCAT  TWIST1  CCCTCGGACAAGCTGAGCAA  TCGCTCTGGAGGACCTGGTA  ASAP3  GTGAAGAGCAGGCCTGGGAA  GAGTGACTGCATGCGCGAAA  ATOH8  GCTGTCCAAACTGGCCATCC  TTGCTGTGGTCGGCACTGTA  GADD45B  GAGGCCCGAGACCTGCATT  CACCAAGCCGTGGCTCTTC  PIM1  GTGCCCATGGAAGTGGTCCT  AACTGTCGGGCCTCTCGAAC  ARHGAP30  TGGGATGGGCTACCTGGAG  TGCCTCATCCAGAGACAGGT  INCA1  AAGTGTTCCAGGGTGGTCAG  GGTGGGCCTTTGATTAAGGT  GRPR  GACAGTGCTGGTGTTTGTGG  TGACAAAGTGGAGCATGGAG  IL24  GCCAGCAAGCTCAGGATAAC  ATAGCAGAAACCGCCTGTGT  ADAMTS12  GTGGGAAACAGTGGCAAGAT  CAAGGATTGGGAAGTGAGGA  DIRAS3  GCCTTCATGGAGATTTCAGC  GCATCTGGGATTTCTTCTCG  SLIT2  GATGTGGCCATTCAGGACTT  TTGTTGCTACATCGGACGAC  TFPI2  CGGATTGAGAACAGGTTTCC  ATTGTCATTCCCTCCACAGC  CTNNBIP1  ATGGGATCAAACCTGACAGC  ATCACCACGTCCTCTGCAC  EPHB1  CCTCCCTAATGTCCCAGGAT  CCTCAGACCAGAAGGCTGAC  CXCL14  CTACAGCGACGTGAAGAAGC  CGCTCTTGGTGGTGATGATA  COL4A6  CTGGCTTTCTTGGCATCAAT  CCAACAGCTCCTTGAGTTCC  ADAMTS6  AAGTCTGCCCTTCAACAACG  ATGTGTCATTCAGCCACCAA  DLC1  CCAGCAACTTGGCAGGCAAT  GCTTCAGGCTCTCCATCCGT  ITGBL1  GTGGTCGCTGTGTGTTTGTGAG  CGAGCACAATATGCCATCTG  WNT10B  CATCCTCAAGCGCGGTTTCC  CTCAGCCGATCCTGCTCACC  SOX7  ATGGTTTGGGCCAAGGACGA  CAGCGCCTTCCACGACTTTC  GAPDH  AGAAGGCTGGGGCTCATTTG  AGGGGCCATCCACAGTCTTC transfected into U87 cells. The successful transfection of Lenti-PRDM13 or Lenti-Con into the U87 cells was confirmed by microscopic green fluorescence detection. As shown in Fig. 1 , the transfection efficiency was >80% by 3 days post-infection with lentivirus. The RT-qPcR data demonstrated that the mRNA expression level of PRdM13 was significantly increased in the Lenti-PRDM13-infected cells (P<0.01; Fig. 2A ). In addition, the protein expression level of Flag-PRdM13, detected by western blot analysis, was markedly increased in the Lenti-PRdM13-infected cells, compared with that in the Nc cells (P<0.01; Fig. 2B ). These data indicated that the PRdM13 gene was effectively overexpressed at the mRNA and protein levels.
Effects of the overexpression of PRDM13 on U87 cells. Tumor cell proliferation is a vital characteristic of tumors. Therefore, it was necessary to examine the impact of the overexpression of PRdM13 on cell proliferation in the U87 cell line. It was demonstrated that cell proliferation was decreased from the third day in the cells infected with Lenti-PRdM13, compared with that in the Nc cells (Fig. 3A) . The role of PRdM13 in the cell cycle of the U87 cells was analyzed by flow cytometry (Fig. 3B) . It was demonstrated that the cell percentage in the G 0 /G 1 phase was increased from 66.66% in the Nc group to 77.34% in the Lenti-PRdM13-infected cells, and the cell percentage in the S phase was decreased to 15.81% from 25.83% (P<0.05). These results indicated that PRdM13 inhibited dNA duplication in the U87 human glioma cells.
The results of the wound-healing assay demonstrated that the migration of U87 cells was lower in the PRdM13 overexpression group than in the Nc group (Fig. 4A) . The results from the Transwell invasion assay demonstrated that the overexpression of PRdM13 suppressed the invasion of U87 cells (Fig. 4B) . The average invasive cell number was 28 in the PRdM13 overexpression group, and 75 in the Nc group (P<0.01; Fig. 4B ). These data showed that the overexpression of PRdM13 may suppress the migration and invasion of U87 cells.
Analysis of transcriptome sequencing data.
To further investigate the mechanisms underlying the effect of the overexpression of PRdM13 in U87 glioma cells, transcriptome sequencing data were analyzed in order to reveal the molecular mechanisms of U87 cells infected with Lenti-PRdM13 or Lenti-control. The volcano plot revealed 760 differentially expressed genes between the two groups, including 222 upregulated genes and 538 downregulated genes (P<0.05; Fig. 5A ). GO analysis revealed three differentially expressed gene functional enrichments: Molecular function, cellular component and biological process. The genes were primarily involved in 'receptor binding', 'molecular function regulator', 'extracellular region part', 'cell periphery', 'system development', 'single-multicellular organism process', 'regulation of multicellular organismal process', 'anatomical structure development' and 'regulation of cell migration' (FdR<0.05; Fig. 5B ).
Significant differential expression in genes between the two groups was analyzed. Following consultation of the relevant literature, it was identified that a number of these genes were involved in tumorigenesis, proliferation and migration, including SRY-Box 7 (SOX7), tumor necrosis factor receptor superfamily member 8 (TNFRSF8), RAR-related orphan receptor α (RORA), early growth response 1 (EGR1), basic helix-loop-helix family, member e41 (BHLHE41), Snail family transcriptional repressor 2 (SNAI2), ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 (ASAP3), Growth arrest and DNA-damage-inducible β (GADD45B), PIM1, AdAMTS12, integrin β-like 1 (ITGBL1), DLC1 and AdAMTS6. These genes have been demonstrated to have a promoting or inhibitory effect on tumors. A number of known inflammatory and immune-associated genes, including interleukin (IL)24, chemokine (c-X-c motif) ligand 14 and interleukin 1 receptor like 1, were also identified. The results of the analyses of these genes is likely to facilitate investigations into the associated mechanisms.
Anti-oncogenes are involved in the PRDM13-mediated progression of glioma cells.
According to the results of transcriptome sequencing data, genes associated with the regulation of cell proliferation and migration were identified from GO sources. A total of 15 upregulated genes and 15 downregulated genes were validated by RT-qPcR analysis. All genes coincided with the results of the transcriptome sequencing data (Fig. 6A) . Of note, the anti-oncogenes dLc1, ARHGAP30, INCA1 and ADAMTS12 were all upregulated at the protein level (Fig. 6B) . The chIP assay demonstrated that PRdM13 may bind to the dLc1 promoter to regulate its expression (Fig. 6C) . As summarized in the diagram in Fig. 6D , PRDM13 may upregulate DLC1 and ARHGAP30, suppressing U87 cell migration, upregulating INcA1 and AdAMTS12, and causing a decrease in U87 cell proliferation.
Discussion
The PRdM family members have been reported to correlate closely with cancer, and the majority are tumor suppressors. PRdM13 is a member of the PRdM family that contains a PR domain and a zinc finger motif (10) . However, the biological function of PRdM13 in glioma has not been elucidated previously. Previous studies have demonstrated that PRdM13 is a transcriptional repressor, which regulates the excitatory/inhibitory balance (11) . In the present study, lower expression levels of PRDM13 were identified in glioma cells survival, including genetic damage detection and repair (12) . The expression of AdAMTS12 has been reported to be associated with a tumor cell anti-proliferation effect by modulating the extracellular signal-regulated kinase signaling pathway. It has also been identified as a novel antitumor protease. It simultaneously induces interstitial cells that may act as part of normal tissues in controlling cancer progression (13) . In the absence of AdAMTS12, angiogenesis and tumor invasion in host tissues increase. El Hour et al (14) reported that AdAMTS12 exhibited anti-angiogenic properties and promoted host defenses against tumors. The expression of AdAMTS12 is associated with tumor histological type, tumor invasion and lymph node metastasis. If the expression of AdAMTS12 is low or missing in the extracellular matrix, the survival rate of the patient is relatively poor. AdASTM12 is important in tumor development; its expression may be a good prognostic indicator in colon cancer (15) . The PRdM13-mediated inhibition of proliferation in glioma is associated with the above proteins.
Among tumor characteristics, invasion and growth are vital for glioma tumors (16) . The results of the present study demonstrated that the overexpression of PRdM13 inhibited the migration and invasion of glioma cells. In order to obtain further insights into the mechanism of PRdM13-associated glioma progression, RNA-Seq analysis for U87 cells overexpressing PRdM13 was performed, and hundreds of genes exhibited significant differential expression. Among them, the gene expression levels of Rho protein and GTP enzyme activation protein were examined in U87 cells. The overexpression of PRdM13 in U87 cells induced upregulation of the expression of DLC1 and ARHGAP30. ChIP was performed to show that PRdM13 was involved with the transcription start site to upregulate the expression of dLc1. These results indicated that PRdM13 inhibited the migration of glioma cells through the upregulation of Rho family proteins.
The Rho family proteins function as important regulators in the organization of the actin cytoskeleton, and dysregulation of the Rho GTPase-associated signaling pathways has been reported in tumors (17) . Low expression levels of ARHGAP30, a Rho GTPase-activating protein, have been reported to be associated with poor survival rates in patients with colorectal cancer (CRC) (18) . ARHGAP30 is required for p53 acetylation and functional activation in cRc, and the expression of ARHGAP30 is a potential prognostic marker for CRC (18) . dLc1, which is associated with human Hcc, is also termed ARHGAP7 and is a Rho GTPase-activating protein. DLC1 has been found to be downregulated in a number of cancer tissues and cells. It has been reported that dLc1 is a tumor suppressor gene in liver cancer in addition to other types of cancer (19, 20) . The dLc-1 gene, deleted in liver cancer at chromosome 8p21-22, is altered primarily by genomic deletion or aberrant promoter methylation in a large number of types of human cancer, including breast, liver, colon and prostate cancer, and is known to have an inhibitory effect on breast and liver tumor cell growth (21) . A feature of many advanced tumors is the activation of the Rho-GTPases RhoA and RhoC. These small GTPases, which are Ras-related proteins, may contribute to various parameters of abnormal cell growth, including viability, migration, invasion, proliferation and anchorage-independent growth (22-24). GTPase-activating protein expression is frequently downregulated or silenced in a variety of human malignancies. The observations in the present study revealed that the overexpression of PRdM13 is likely to be associated with the GTPase-activating proteins, inhibiting glioma cell migration. In the future, it may be worthwhile to investigate the mechanism underlying PRdM1-mediated Rho protein expression.
In conclusion, the present study demonstrated that PRdM13 was important in glioma cell malignant progression in vitro, as the overexpression of PRdM13 prevented proliferation, migration and invasion. Verhaak et al (25) reported the gene expression-based molecular classification of GBM into proneural, neural, classical, and mesenchymal subtypes. Aberrations and gene expression of epidermal growth factor receptor, neurofibromin 1, and platelet derived growth factor receptor α/isocitrate dehydrogenase 1 each define the different subtypes, Their findings were from brain tissues of patients. The findings of the present study are significant, however, the role of PRdM13 on glioma cells was discussed using the U87 cell line in vitro only. This was a limitation of the present study and future investigations into the detailed molecular mechanisms of the role of PRdM13 in glioma are required. These results provide the biological basis for a novel therapeutic approach in glioma.
